CSL (CMXHF) Debt-to-Asset : 0.32 (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is CSL Debt-to-Asset?

CSL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $944 Mil. CSL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $11,239 Mil. CSL's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $38,022 Mil. CSL's debt to asset for the quarter that ended in Jun. 2024 was 0.32.

CSL Debt-to-Asset Historical Data

The historical data trend for CSL's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Debt-to-Asset Chart

CSL Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.39

0.32

0.34

0.32

CSL Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.34	0.34	0.34	0.33	0.32

Competitive Comparison of CSL's Debt-to-Asset

For the Biotechnology subindustry, CSL's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where CSL's Debt-to-Asset falls into.

CSL Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

CSL's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(944	+	11239)	/	38022
	=	0.32

CSL's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(944	+	11239)	/	38022
	=	0.32

CSL (OTCPK:CMXHF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

CSL Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of CSL's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CSJA:Germany CSJ:Germany CSJ:Germany CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.